SCHEMBL25899572

SCHEMBL25899572

CN1Cc2cnn(C)c2-c2cccc(NC(=O)OC(C)(C)C)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.39
PDE5A O76074 2/20 0.37
PDE4A P27815 2/20 0.37
PDE1A P54750 2/20 0.37
PDE1B Q01064 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37
PDE4D Q08499 2/20 0.37
PDE3B Q13370 2/20 0.37
PDE1C Q14123 2/20 0.37
PDE3A Q14432 2/20 0.37
BRD9 Q9H8M2 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
DRD2 P14416 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
METAP1 P53582 1/20 0.34
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766668 1.00 IDO1 (0.39) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL26967782 0.84 HIF1A (0.34) BRD9TRPV1
SCHEMBL25901670 0.82 IDO1 (0.35) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL29766654 0.82 IDO1 (0.35) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL25897321 0.80 MEN1 (0.39) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL29865987 0.79 IDO1 (0.40) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL29766580 0.79 BRD9 (0.37) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL25899570 0.79 BRD9 (0.37) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL29766576 0.76 TYK2 (0.37) IDO1PDE5APDE4APDE1APDE1B
SCHEMBL29766648 0.73 IDO1 (0.35) IDO1PDE5APDE4APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024042361-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2024-02-29 WO disclosed
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS TYK2, PDXK, JAK1 IDO1 211/4885PDE5A 3860/4885PDE4A 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.